Drugs / M01ZH09
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01405521 | Oct 2011 → Dec 2015 | typhoid fever | University of Oxford | Completed | Missed primary |
| Phase 2 | NCT00679172 | May → Dec 2008 | typhoid fever | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M01ZH09 | “Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.” PMID 27533046 ↗ Aug 20161“Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults” NCT00679172 ↗ |
| Known as | S. Typhi (Ty2 Delta aroC Delta ssaV) ZH9 | “M01ZH09, S. Typhi (Ty2 Delta aroC Delta ssaV) ZH9, is a single oral dose typhoid vaccine with independently attenuating deletions.” PMID 20188175 ↗ Feb 2010 |
| Modality | Vaccine | “single oral dose typhoid vaccine” PMID 20188175 ↗ Feb 2010 |
| Route | Oral | “single oral dose” NCT00679172 ↗ |